Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Moderna has reported positive phase 3 results for its seasonal flu vaccine, mRNA-1010, which outperformed a standard-dose ...

Moderna Inc (NASDAQ:MRNA) saw its stock rise 3.8% after announcing that its experimental flu vaccine, mRNA-1010, delivered ...

Moderna today reported promising relative vaccine efficacy (rVE) findings from a phase 3 trial of its seasonal mRNA flu ...

Moderna's flu vaccine candidate, mRNA-1010, shows 26.6% efficacy in a Phase 3 trial for adults 50+. Read more here.

At 21-42 days post-vaccination, the geometric mean haemagglutination inhibition titres were 32% higher for H1N1, 55% for H3N2, and 39% for B strains among recipients of the high-dose vaccine than ...

A confirmed H1N1 outbreak has hit Anum Senior High School, with all nine samples from the school testing positive.

The most likely explanation is that older adults were exposed to a similar strain - another type of H1N1 - that was the primary flu in circulation from about 1918 to 1957. After 1957, a different ...

H1N1 is a pandemic, meaning it is a global epidemic. It's the first flu pandemic in 41 years. The federal response looks like a war room, but the officers are in the U.S. public health service, ...